SCHEMBL4357558

SCHEMBL4357558

O=S(=O)(Cc1ccccc1)Nc1ccc(O)cc1O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACLY P53396 1/20 0.51
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
MMP1 P03956 1/20 0.50
MMP2 P08253 1/20 0.50
MMP9 P14780 1/20 0.50
MMP8 P22894 1/20 0.50
MMP13 P45452 1/20 0.50
PGAM1 P18669 1/20 0.49
ALDH1A1 P00352 3/20 0.48
MAPK1 P28482 1/20 0.48
PTK2B Q14289 1/20 0.48
AR P10275 1/20 0.47
KMT2A Q03164 2/20 0.46
GLO1 Q04760 1/20 0.46
HPGD P15428 3/20 0.46
KDM4E B2RXH2 2/20 0.44
PGR P06401 1/20 0.44
PARP14 Q460N5 1/20 0.44
MEN1 O00255 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4347808 0.85 ALDH1A1 (0.56) ACLYCA1CA2MMP1MMP2
SCHEMBL6566936 0.83 CA1 (0.56) ACLYCA1CA2MMP1MMP2
SCHEMBL11640095 0.78 EP300 (0.59) ACLYCA1CA2MMP1MMP2
SCHEMBL6567551 0.77 KMT2A (0.70) CA1CA2MMP1MMP2MMP9
SCHEMBL8956206 0.76 KMT2A (0.55) CA1CA2MMP1MMP2MMP9
SCHEMBL6567611 0.76 PTGES2 (0.55) ACLYCA1CA2MMP1MMP2
SCHEMBL3262497 0.76 ERBB2 (0.71) MMP2PGAM1ALDH1A1MAPK1KMT2A
SCHEMBL4357672 0.74 GLO1 (0.51) ACLYCA1CA2MMP1MMP2
SCHEMBL11742060 0.73 ALDH1A1 (0.52) ACLYCA1CA2MMP1MMP2
SCHEMBL4343432 0.73 KMT2A (0.51) ACLYCA1CA2MMP1MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-1539683-A2 PHENOL DERIVATIVES AND THEIR USE AS ROTAMASE INHIBITORS Jerini AG (DE) 2005-06-15 EP claimed
WO-2004030664-A2 NEW COMPOUNDS FOR THE INHIBITION OF UNDESIRED CELL PROLIFERATION AND USE THEREOF JERINI AG (DE) 2004-04-15 WO claimed
WO-2004026815-A2 PHENOL DERIVATIVES AND THEIR USE AS ROTAMASE INHIBITORS JERINI AG (DE) 2004-04-01 WO claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 ACLY 581/4885CA1 374/4885CA2 2053/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 ACLY 905/4885CA1 532/4885CA2 1651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.